As trials have demonstrated its efficacy in psoriatic arthritis, and more importantly in those previously exposed to TNF inhibitors, it was also approved for active psoriatic arthritis, alone or in combination with methotrexate (McInnes et al., 2013; Kavanaugh et al., 2014; Ritchlin et al., 2014). This evidence concerns the gene TNF and psoriatic arthritis.